The present investigation was conducted to evaluate the effect of penconazole (PEN) fungicide on early embryogenesis of white mice. In the first experiment, 48 pregnant females were divided into different groups; the first group is control (G1). The second group (G2) was treated daily with PEN (30-, 20-, 10-, 5-mg/kg BW). The third group (G3) was treated with PEN (5-mg/kg BW; day after the other day). The fourth group (G4) was treated with PEN (2.5-mg/kg BW daily) during pre-implantation stage (from the 1st to the 4th day of gestation). The fifth group (G5) was treated with PEN (2.5-mg/kg BW daily) during post-implantation (from the 5th to the 8th day of gestation). The pregnant females were sacrificed at the 14th day of gestation. In the second experiment, 63 pregnant females were classified into control, PEN-treated during pre-implantation period (2.5-mg/kg BW), and PEN-administered during post-implantation period (2.5-mg/kg BW). Each group was sacrificed at stages E6.5, E7.5, E8.5, E9.5, E11.5, E14.5, and E18.5. The high doses of PEN in the first experiment showed failed pregnancy, foetoresorption, and embryo disorganization. High doses of PEN induce alterations in the uterus tissue at the level of histology and immunohistochemistry for the expression of TGFβ2, TNFR2, Caspase 10, and HSP70. The low doses of PEN in the second experiment showed upregulated expression of TGFβ2, TNFR2, Caspase 10, and HSP70 at stages E6.5 and E7.5. In conclusion, PEN was found to alter the suitable uterine environment for proper implantation and development at the levels of histological and immunohistochemical that could create a risk during the full course of embryogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11356-020-07637-3DOI Listing

Publication Analysis

Top Keywords

group treated
16
pregnant females
12
treated pen
12
day gestation
12
doses pen
12
pen
9
early embryogenesis
8
embryogenesis white
8
white mice
8
experiment pregnant
8

Similar Publications

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.

Hum Vaccin Immunother

December 2025

Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).

View Article and Find Full Text PDF

Breast cancers of the IntClust-2 type, characterized by amplification of a small portion of chromosome 11, have a median survival of only five years. Several cancer-relevant genes occupy this portion of chromosome 11, and it is thought that overexpression of a combination of driver genes in this region is responsible for the poor outcome of women in this group. In this study we used a gene editing method to knock out, one by one, each of 198 genes that are located within the amplified region of chromosome 11 and determined how much each of these genes contributed to the survival of breast cancer cells.

View Article and Find Full Text PDF

Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.

Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.

View Article and Find Full Text PDF

External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.

JAMA Netw Open

January 2025

Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.

View Article and Find Full Text PDF

Perfusion Capacity as a Predictive Index for Assessing Visual Functional Recovery in Patients With Idiopathic Epiretinal Membrane.

Transl Vis Sci Technol

January 2025

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.

Purpose: This study investigates the association between visual function and retinal vasculature metrics, particularly perfusion capacity (PC), in eyes with idiopathic epiretinal membrane (iERM), using optical coherence tomography angiography (OCTA).

Methods: This retrospective study includes 30 eyes from 30 iERM patients who had surgery, with a three-month follow-up period. In addition, 28 eyes from 28 healthy individuals served as a control group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!